

10/820, 816

AMENDMENTS TO THE SPECIFICATION:

Please amend page 11, lines 16-19, of the specification as follows:

The present invention also relates to nucleic acids encoding SEQ ID Nos. 1 to 9, such as the CBD-1, CBD-2, CBM-1/TH-1, ~~CBM-1-TH-2~~CBM-1/TH-2, CBM-2/TH-2 and CBM-2/TH-1 peptide sequences or variants of these peptide sequences, such as, for example, SEQ ID Nos. 11 to 18.

— please amend page 22 lines 21-31, of the Specification as follows.

[0119] In addition buffering agents and adjuvants can comprise part of the vaccine or pharmaceutical composition formulation. Various adjuvants that are known in the art that can be used in the vaccine or pharmaceutical formulations include Complete Freund's Adjuvant (CFA), Incomplete Freund's Adjuvant (IFA), motanide ISA (incomplete seppic adjuvant), the Ribi adjuvant system (RAS), Titer Max, muramyl peptides, Syntex Adjuvant Formulation (SAF), alum (aluminum hydroxide and/or aluminum phosphate), aluminum salt adjuvants, Gerbu[®]. adjuvants, nitrocellulose absorbed antigen, encapsulated or entrapped antigen, immuno-stimulating complexes, such as Quil A, QS-21 and the like. Still other adjuvants are CpG oligonucleotides and double stranded RNA molecules, such as poly(A).poly(U). Combinations of the above adjuvants also encompass part of the vaccine or pharmaceutical compositions of the present invention.

28
1/11/08.